Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) has announced that it has regained compliance with the NYSE American's continued listing standards, resolving a previously reported deficiency related to its low selling price.

Rhea-AI Summary

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) has announced that it has regained compliance with the NYSE American's continued listing standards, resolving a previously reported deficiency related to its low selling price. Effective December 27, 2022, the company will no longer be indicated as noncompliant and has been removed from the NYSE American noncompliant issuers list. Ampio is currently focused on the development of AR-300, a synthetic drug in preclinical studies, while exploring strategic alternatives to enhance its pipeline.

Positive

• Regained compliance with NYSE American listing standards.
• Removed from noncompliant issuers list.

Negative

• None.

Argus Session date unavailable

+0.68% session move Open Argus

Details

News Market Reaction – AMPE

The recorded move for AMPE in the trading session of this news was +0.68%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ENGLEWOOD, Colo., Dec. 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide. 

In the notification, the NYSE American informed the Company that as of December 27, 2022, the below compliance (".BS") indicator will no longer be disseminated and the Company has been removed from the NYSE American noncompliant issuers on the NYSE American's website.

About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc. is a pre-revenue stage biopharmaceutical company that is engaged with the early development of AR-300, a synthetic pre-clinical stage development asset which has been designed to leverage the key attributes of Ampion. The Company is currently conducting preclinical studies on AR-300 and engaged in a strategic alternatives process that could include outbound strategic in-licensing / acquisition efforts with a key focus on late-stage development assets / programs which would strengthen its existing pipeline.

For more information, contact:

Ampio Pharmaceuticals, Inc.
Michael Martino
Chief Executive Officer
mmartino@ampiopharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-regains-compliance-with-nyse-american-continued-listing-standards-301710404.html

SOURCE Ampio Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ampio Pharmaceuticals announce on December 27, 2022?

Ampio Pharmaceuticals announced that it has regained compliance with the NYSE American's continued listing standards.

What is the stock symbol for Ampio Pharmaceuticals?

The stock symbol for Ampio Pharmaceuticals is AMPE.

Why was Ampio Pharmaceuticals previously noncompliant with NYSE American?

Ampio Pharmaceuticals was previously noncompliant due to a low selling price.

What is AR-300 in relation to Ampio Pharmaceuticals?

AR-300 is a synthetic drug in preclinical development by Ampio Pharmaceuticals.

What does it mean that Ampio Pharmaceuticals removed its noncompliance status?

It means the company meets the required standards for continued listing on the NYSE American.